Open danaklug opened 4 years ago
Yes, it'd be very good to secure some of these data. The very high intrinsic clearance of the main compound is a problem, and it'd important to know whether such data were obtained for other compounds, and whether we could easily ship to Monash for evaluation. @AlvaroLor - who's the best person to contact about supplies at Chapel Hill? Do you know if CLint was measured for other members of the series (ping @TwistedSwisster )? If there are samples (I'd suggest actives and inactives maybe?) I can reach out to Monash, who I think are not yet on Github.
The entire compound library is at UNC and there are at least 15 mg of each compound. I think the clearance studies are typically performed by using a range of drug concentrations, so I would say that a couple of mg is more than enough, although is better to ask Monash what do they need. Could you please contact with them? I can contact with people from the UNC lab to help us with the shipment. On the other hand, I think MRSA MIC values were the only measurements done with CO-ADD but @TwistedSwisster knows it better. Hopefully, we will be able confirm/compare the predicted metabolic liabilities with the clearance in vitro values!
That's great, thank you for checking whether you still have samples for shipping. I will reach out to Monash to double-check that they are OK with testing clearance. Can you (@AlvaroLor ) ot @TwistedSwisster confirm that no other compounds in this series were measured for microsomal clearance, so that we will be asking Monash for new measurements?
For easy reference, here is the summary of clearance data we have on focused array compounds (also on the wiki, linked above):
Looking at the clearance data for SB-400868 and OSA_000813, both are fairly highly cleared (although more stable than OSA_000822), which indicates that the benzothiophene is not the only metabolic liability of this series. I ran both compounds through SMARTCyp; the results (below) indicate that the methylenes are likely to be labile (this is also supported by the MetaSite and SMARTCyp analyses of OSA_000822).
A few suggestions for future testing:
If Monash provide HLM data, we should send SB-400868, OSA_000813, and OSA_000822 as this would be new and valuable information.
I think that OSA_000814 and OSA_000821 would also be interesting to test at Monash. Although 814 isn’t particularly active, clearance data would give a good idea of the role of the core methylenes when compared to SB-400868. 821 is only slightly less active than the lead thiophene 822 and may be an interesting alternative.
This is really good @danaklug . The deal we have in the small grant we won to look at this series is that there are funds for 9 in vitro panels at Monash ("Kinetic solubility at pH 2 and 6.5, logD determination and metabolic stability in liver microsomes (human, rodent) for 9 compounds"). So if we sent these five, we'd have space for 4 more, which is OK from my perspective. Note also we have funds for one in vivo, at the end, "In vivo rat pharmacokinetics (IV/PO) including formulation and LCMS development, collection of plasma concentration vs. time profile (24 h) and determination of PK properties for 1 compound". Maybe we should acquire rat microsomal data as a result? @TwistedSwisster @AlvaroLor did you have a sense of whether mouse or rat is preferable, given the likely animal we might use to assess in vivo PK? ping @rhanson1046
@danaklug @mattodd I would expect the benzofuran of OSA_000821 to be another metabolic hotspot. Do we have any with an electron-deficient ring?
@drc007 No, not really. With 821 I was hoping we would get an idea of the clearance of another active compound. However, I don't think that data would be crucial to decisions going forward, so we could always table that one and save the slot.
@danaklug benzothiophene‐1,1‐diones are known, and a quick search suggests a number of potential building blocks are available. Not a structural class I am that familiar with.
@mattodd We have used rat, mouse, rabbit or human liver microsomes to evaluate the metabolic stability of different small molecule libraries, but we selected them based on prior studies. However, there is not any previous stability study available for this compound family. On the "Surrounding Chemical Space and Literature" post, @danaklug listed some papers related with 4,5-diaryl-imidazoles, most of them are pure synthesis but in this recent one: https://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.9b00552?journalCode=amclct&quickLinkVolume=11&quickLinkPage=172&selectedTab=citation&volume=11 they evaluated PK properties and metabolic liabilities of diaryl imidazoles using mouse, rat, human and dog microsomes. So I think either rat or mouse are fine, but if the in vivo studies are going to be performed with rats, it makes sense to use rat microsomes as the preferred choice.
UPDATE: The following 5 compounds have now all been sent to Monash for clearance measurements. Results will be posted when received.
Thanks for the update and good luck. Bob Hanson
From: Edwin Tse notifications@github.com Sent: Tuesday, September 1, 2020 12:35 PM To: opensourceantibiotics/Series-2-Diarylimidazoles Series-2-Diarylimidazoles@noreply.github.com Cc: Hanson, Robert r.hanson@northeastern.edu; Mention mention@noreply.github.com Subject: Re: [opensourceantibiotics/Series-2-Diarylimidazoles] Clearance data - focused array compounds (#13)
UPDATE: The following 5 compounds have now all been sent to Monash for clearance measurements. Results will be posted when received.
— You are receiving this because you were mentioned. Reply to this email directly, view it on GitHubhttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fopensourceantibiotics%2FSeries-2-Diarylimidazoles%2Fissues%2F13%23issuecomment-684985026&data=02%7C01%7Cr.hanson%40northeastern.edu%7Cfe8bc6bd5e0a4059fe4c08d84e9512df%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637345749916718993&sdata=F0zNkpvTl6WNWgLG8m6CGe%2Fi9Sd17n5t3ZEa50IUmCY%3D&reserved=0, or unsubscribehttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fnotifications%2Funsubscribe-auth%2FANGWX5MI6L22JKLHSHK5GZDSDUPF7ANCNFSM4NHXZ5LA&data=02%7C01%7Cr.hanson%40northeastern.edu%7Cfe8bc6bd5e0a4059fe4c08d84e9512df%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637345749916723967&sdata=gCN%2FzjNTOvfRYV4y1DXNMN4K9sU0vofT7P7IWc2qkkU%3D&reserved=0.
Karen White has asked "mouse or rat"? It makes sense I think to go for rat, given that that is the in vivo experiment we're aiming for. @AlvaroLor agrees. Any advocates for mouse data?
@mattodd Priorities should be in vivo efficacy species and probable species to be used in safety studies, so rat seems appropriate.
Monash results have been posted to the wiki and will be discussed in today's project meeting (25 Sept. 2020).
Thanks for the update. I have downloaded the MRSA data and the drug metabolism results and will give some thought to them. R. Hanson Department of Chemistry and Chemical Biology Northeastern University
From: Dana Klug notifications@github.com Sent: Friday, September 25, 2020 8:31 AM To: opensourceantibiotics/Series-2-Diarylimidazoles Series-2-Diarylimidazoles@noreply.github.com Cc: Hanson, Robert r.hanson@northeastern.edu; Mention mention@noreply.github.com Subject: Re: [opensourceantibiotics/Series-2-Diarylimidazoles] Clearance data - focused array compounds (#13)
Monash results have been posted to the wikihttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fopensourceantibiotics%2FSeries-2-Diarylimidazoles%2Fwiki%2FMetabolic-Clearance-Data&data=02%7C01%7Cr.hanson%40northeastern.edu%7C97acbf6eac9b4277114208d8614ee60f%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637366338780806751&sdata=wFM7irF9oRR9A8kNIQ5ddFXMueFUd4ZzJJkxI%2F0HXvw%3D&reserved=0 and will be discussed in today's project meetinghttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fopensourceantibiotics%2FSeries-2-Diarylimidazoles%2Fissues%2F29&data=02%7C01%7Cr.hanson%40northeastern.edu%7C97acbf6eac9b4277114208d8614ee60f%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637366338780816745&sdata=DYAe7TQr5qF0qa5Tvp6asKYmM%2FGd2ASEITKCBub%2BwtY%3D&reserved=0 (25 Sept. 2020).
— You are receiving this because you were mentioned. Reply to this email directly, view it on GitHubhttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fopensourceantibiotics%2FSeries-2-Diarylimidazoles%2Fissues%2F13%23issuecomment-698901210&data=02%7C01%7Cr.hanson%40northeastern.edu%7C97acbf6eac9b4277114208d8614ee60f%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637366338780816745&sdata=sB5txUVuzgsfdYj1e9AK%2Bny7g4HJlYv4yKqi24ZPhbU%3D&reserved=0, or unsubscribehttps://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgithub.com%2Fnotifications%2Funsubscribe-auth%2FANGWX5I7PEWKJZNHVCVJZ7LSHSERJANCNFSM4NHXZ5LA&data=02%7C01%7Cr.hanson%40northeastern.edu%7C97acbf6eac9b4277114208d8614ee60f%7Ca8eec281aaa34daeac9b9a398b9215e7%7C0%7C0%7C637366338780826742&sdata=oTZeH8cPZ4rOWwefw3XpWbFPRNQbTbhNKsTCCPKaBbM%3D&reserved=0.
In thinking about which compound to send for evaluation of metabolite formation (#29) our friends at Hypha asked whether we have done any metasite predictions on the compound we'd like to ship (OSA821 - the benzofuran). I'm not sure we have, have we? @drc007 @danaklug @AlvaroLor @TwistedSwisster ? They mentioned a paper we might want to check out related to this (https://www.mdpi.com/2073-4344/10/1/62). The proof will be in the pudding (is the furan being oxidised, or the pyridyl?), but chance favours the prepared mind, I guess.
As part of optimizing the clearance of OSA_000822, it would be great to get some clearance data on the related analogs synthesized by @AlvaroLor. A few questions so that we can get this off the ground:
@AlvaroLor Are there samples of focused array compounds at UNC that could be sent to Monash?
How much compound is required for clearance assays?
Are these compounds accessible currently and is Monash able to receive them?